The recent FDA rejection of MDMA-assisted therapy for PTSD put forth by Lykos Therapeutics has left the psychedelic drug development and mental health communities at a critical juncture, reigniting discussions about the future of innovative mental health treatments. As the industry faces this significant setback, the question emerges: where do we go now?

Psychedelics biotech Enveric Biosciences ENVB announced positive preclinical results of its EB-003 drug candidate to be delivered via oral administration. EB-003 is a new, neuroplastogenic molecule designed to treat serious mental health disorders without the hallucinogenic effect typically associated with DMT (N,N-Dimethyltryptamine) and other psychedelic compounds. The results indicate that oral administration of EB-003 provides […]

Enveric Biosciences, a forward-thinking biotechnology company specializing in neuroplastogenic treatments for neuropsychiatric disorders, has announced preclinical results that underscore the potential of their novel drug candidate, EB-003. These findings, detailed in a recent press release, highlight the drug’s oral bioavailability and significant brain exposure, positioning it as a promising treatment for severe mental health conditions.

With the UK general election set for July 4th, 2024, housing is poised to be a key topic. Let’s explore how election predictions might affect the supported living and social housing market, and what this could mean for housing investments.

The wealth of young Americans has grown rapidly after years of stagnation, thanks to the strong recovery of the U.S. economy. Data compiled by the Center for American Progress (CAP) has found that Americans aged under 40 are outpacing other age groups when it comes to accumulated wealth, employment rates and wage growth following the […]

A month ago Crunchbase published an article titled “Megadeals explode early in the year as U.S. startups gobble up more $100 million+ rounds.” Indeed, with 115 funding rounds surpassing the $100 million mark, the amount of megadeals is already above last year’s 73 deals. Among the startups raising these substantial amounts, biotech and healthcare companies […]

This past week, an FDA advisory committee voted 9-2 to reject the validity of therapy-assisted MDMA clinical trials conducted by Lykos Therapeutics for the treatment of PTSD.

As a biotechnology company, Enveric is dedicated to the development of novel neuropathogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders.

Ketamine can provide relief from mental health conditions in hours. Compare that with the weeks it may take other therapies, and the allure for both providers and their patients is clear.

This partnership represents a significant move toward utilizing psychedelic medicines to manage mental health disorders without the typical hallucinogenic effects.